Clinical Trial Update: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes [Phase 3]

View source ↗

Summary

An update on a Phase 3 master protocol evaluating Orforglipron (LY3502970) for obesity or overweight in participants with and without Type 2 Diabetes. The study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight
• Type 2 Diabetes Mellitus

Drugs mentioned

• Orforglipron (orforglipron)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obesity, Overweight | Phase 3 | Status: ACTIVE_NOT_RECRUITING